The statistical methods scientists use to analyze outcomes from clinical trials in amyotrophic lateral sclerosis (ALS) vary widely, and these differences may make some trials prone to generating misleading results, a study found. The researchers focused on analysis of the ALS Functional…
Varying data analysis in ALS trials can muddle results, study finds
Two leaders at Brainstorm Cell Therapeutics, which is developing the experimental cell-based therapy NurOwn (debamestrocel) for people with amyotrophic lateral sclerosis (ALS), have published a paper calling on the U.S. Food and Drug Administration (FDA) to modernize its review process for experimental therapies for ALS and other…
Several nonprofits are uniting to fund new research aimed at identifying targets for the treatment of amyotrophic lateral sclerosis (ALS). The new initiative will be led by the Allen Institute, a nonprofit medical research organization, through its Brain Health Accelerator — a research initiative to study neurodegenerative diseases. The…
My husband, Todd, and I just finished watching the TV series “Person of Interest,” about a type of super artificial intelligence (AI) that predicts crime. The series, which ran from 2011 to 2016, was prescient about current issues resulting from AI and mass surveillance. In the penultimate episode, one of…
PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan drug designation by the U.S. Food and Drug Administration for the treatment of amyotrophic lateral sclerosis (ALS). The status aims to accelerate the development of therapies for rare diseases, or…
I am always looking for ways to simplify my life and help my days go by a bit more smoothly. But when you live with ALS, like I do, there is always one extra thing to do, plan, or think about before you can even begin an activity. It’s…
An arm of the HEALEY ALS platform trial testing Neurizon Therapeutics’ experimental therapy NUZ-001 as a treatment for amyotrophic lateral sclerosis (ALS) is expanding enrollment from 160 to as many as 240 participants. The decision follows enrollment that exceeded original expectations and the absence of another HEALEY regimen…
Regulatory authorities in the Netherlands have given the green light for a clinical trial testing Ability Neurotech‘s experimental brain-implantable technology as a way to restore communication and speech in people with amyotrophic lateral sclerosis (ALS). The study is designed to assess whether the system can support independent communication…
Tomorrow, June 2, is Lou Gehrig Day, an annual event that honors the life and legacy of Lou Gehrig, the record-setting baseball player who died from amyotrophic lateral sclerosis (ALS) more than 80 years ago. Major League Baseball (MLB) designated June 2 to honor Gehrig because it marks when…
French actor Pierre Deny, known for his role in the Netflix streaming series “Emily in Paris,” has died from amyotrophic lateral sclerosis (ALS) at age 69. “It is with deep emotion that we announce the passing of Pierre Deny, which occurred this Monday following a sudden and severe case of…
Recent Posts
- This ALS caregiver is learning to hit the pause button
- Oral prosetin proves safe in early trial, paving way for Phase 2
- Adult children of parents with ALS may need more support, study finds
- A funny thing happened on the way to the ALS forums
- Motor neuron diseases are on the increase in Europe, study finds